References
- Bentall, R.P. (2003). Madness Explained: Psycho-sis and Human Nature. London: Penguin.
- Cornblatt, B.A., Lencz, T. & Kane, J.M. (2001). Treatment of the schizophrenia prodrome: Is is presently ethical? Schizophrenia Research, 51, 31 — 38.
- Cornwell, J. (1996). The Power to Harm: Mind, Murder and Drugs on Trial. London: Penguin Books.
- French, P., Morrison, A.P., Walford, L., Knight, A. & Bentall, R.P. (2003). Cognitive therapy for preventing transition to psychosis in high risk individuals: A case series. Behavioural and Cognitive Psychotherapy, 31, 53–68.
- Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal, 321, 1371–1376.
- Healy, D. (2002). Conflicting interests in Toronto: Anatomy of a controversy at the interface of academia and industry. Perspectives in Biology and Medicine, 45, 250–263.
- Le Fanu, J. (1999). The Rise and Fall of Modern Medicine. London: Little, Brown and Co.
- Lexchin, J., Bero, L.A., Djulbegovic, B. & Clark, 0. (2003). Pharmaceutical industry sponsor-ship and research outcome and quality: systematic review. British Medical Journal, 326(7400), 1167–1170.
- McGorry, P.D., Yung, A.R., Phillips, Li., Yuen, H.P., Francey, S., Cosgrave, EM., Germano, D., Bravin, J., McDonald, T., Blair, A., Adlard, S. & Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthres-hold symptoms. Archives of General Psychia-try, 59(10), 921–928.
- Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased med-icine—selective reporting from studies spon-sored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal, 326(7400), 1171–1173.
- Whitaker, R. (2002). Mad in America: Bad science, bad medicine and the enduring mistreatment of the mentally ill. New York: Perseus Books.